NASDAQ:VRSK 11 February 2026

March 24, 2026, 9:45 AM EDT. Alkermes (NASDAQ:ALKS) saw its price target cut by Piper Sandler from $45.00 to $43.00, indicating a 55.18% upside despite a cautious outlook. The biotech firm's recent earnings missed expectations with a $0.29 EPS against the forecasted $0.43, while revenue slightly exceeded estimates at $384.55 million but declined 10.6% year-over-year. Analyst ratings vary, with a consensus "Moderate Buy" and an average target price near $43.93. Alkermes stock opened Tuesday at $27.71, near its 52-week low, reflecting market concerns after mixed signals from multiple brokerages. Insider selling was noted, as EVP Craig Hopkinson offloaded 9,000 shares at $29.72 each. The company projects negative EPS for fiscal 2026, pressure that tempers investor enthusiasm.